Jeffries Global Healthcare Conference in London

An exciting week ahead as our CEO Jan Thirkettle heads to London Life Sciences Week, 17-20 November, to meet with life science leaders and investors to discuss Harness' innovative approach to tackling neurodegenerative diseases.

Jan will be speaking at the SV Health Investors panel on Huntington's Disease (HD) on the 17 November, sharing how recent insights into the biology of the disease and new biomarkers are enabling a new class of therapeutics to be developed with the potential to change the course of HD even before symptoms develop. He'll also provide an update on Harness’ FAN1 programme for HD, and how our MISBA® platform for controlled upregulation was key to prosecuting this important target.

If you're in London around Jefferies Global Healthcare Conference and would like to connect, please get in touch!

hashtag#HarnessTherapeutics hashtag#MISBA hashtag#HuntingtonsDisease hashtag#NeurodegenerativeDiseases hashtag#LondonLifeSciencesWeek hashtag#JefferiesHealthcare

Our programmes

Huntington's Disease

Discover more

ALS and Alzheimer's

Discover more

Our news

February 2026

Harness Therapeutics Nominates HRN001, a First-in-Class Drug Candidate for Huntington’s Disease and Establishes Clinical Advisory Board

October 2025

Harness Therapeutics Announces Launch of MISBA® Duo Platform and Research Collaboration with Ono Venture Investment

June 2025

Harness Therapeutics Publishes HTT CAG Repeat Sizing Methodology Code on GitHub

February 2025

Harness Therapeutics to Present Nanopore Sequencing Data for Detecting CAG Expansion in the Huntingtin Gene at CHDI Huntington’s Disease Therapeutics Conference

View all